User: Guest  Login
Document type:
Journal Article; Article
Bembenek, AE; Rosenberg, R; Wagler, E; Gretschel, S; Sendler, A; Siewert, JR; Nährig, J; Witzigmann, H; Hauss, J; Knorr, C; Dimmler, A; Gröne, J; Buhr, HJ; Haier, J; Herbst, H; Tepel, J; Siphos, B; Kleespies, A; Koenigsrainer, A; Stoecklein, NH; Horstmann, O; Grützmann, R; Imdahl, A; Svoboda, D; Wittekind, C; Schneider, W; Wernecke, KD; Schlag, PM
Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial.
INTRODUCTION: The clinical impact of sentinel lymph node biopsy (SLNB) in colon cancer is still controversial. The purpose of this prospective multicenter trial was to evaluate its clinical value to predict the nodal status and identify factors that influence these results. METHODS: Colon cancer patients without prior colorectal surgery or irradiation were eligible. The sentinel lymph node (SLN) was identified intraoperatively by subserosal blue dye injection around the tumor. The SLN underwent step sections and immunohistochemistry (IHC), if classified free of metastases after routine hematoxylin and eosin examination. RESULTS: At least one SLN (median, n = 2) was identified in 268 of 315 enrolled patients (detection rate, 85%). Center experience, lymphovascular invasion, body mass index (BMI), and learning curve were positively associated with the detection rate. The false-negative rate to identify pN+ patients by SLNB was 46% (38 of 82). BMI showed a significant association to the false-negative rate (P < 0.0001), the number of tumor-involved lymph nodes was inversely associated. If only slim patients (BMI < or =24) were investigated in experienced centers (>22 patients enrolled), the sensitivity increased to 88% (14 of 16). Moreover, 21% (30 of 141) of the patients, classified as pN0 by routine histopathology, revealed micrometastases or isolated tumor cells (MM/ITC) in the SLN. CONCLUSIONS: The contribution of SLNB to conventional nodal staging of colon cancer patients is still unspecified. Technical problems have to be resolved before a definite conclusion can be drawn in this regard. However, SLNB identifies about one fourth of stage II patients to reveal MM/ITC in lymph nodes. Further studies must clarify the clinical impact of these findings in terms of prognosis and the indication of adjuvant therapy.
Journal title abbreviation:
Ann Surg
Journal volume:
Journal issue:
Pages contribution:
Fulltext / DOI:
Pubmed ID:
TUM Institution:
Chirurgische Klinik und Poliklinik; Institut für Allgemeine Pathologie und Pathologische Anatomie